SPX 0.02% VIX 2.34%
DOW, NASDAQ POST RECORD CLOSE AS STOCKS EDGE HIGHER 
STOCKS UNDER INCREASING PRESSURE MONDAY AS SECOND-QUARTER EARNINGS SEASON OPENS 
SYMANTEC SHARES PLUNGE ON REPORTED HALT IN BROADCOM DEAL TALKS 
NEW YORK FED'S MANUFACTURING GAUGE SHOWS JULY REBOUND 
NEED TO KNOW: HOW STOCK-MARKET INVESTMENTS ARE LIKE FYRE FESTIVAL TICKETS 
CITI SHARES UP IN PREMARKET AFTER SALES AND PROFIT RISE 
CALLON PETROLEUM SAYS IT WILL BUY CARRIZO OIL & GAS FOR $3.2 BILLION 
U.S. STOCKS END AT RECORD HIGHS, FUELED BY OPTIMISM OVER FED INTEREST-RATE CUTS 
FACEBOOK STOCK MOVES HIGHER AFTER REPORT OF $5 BILLION FTC SETTLEMENT 
THERE ARE 5 THINGS ATOP INVESTORS' MINDS AS EARNINGS SEASON IS ABOUT TO BEGIN 
Mon, Jul 15 6:37pm

Compare BMRN



BioMarin Pharmaceutical Inc [BMRN]
$83.99 1.04 (1.25%)

BMRN Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 14.85 Billion
BMRN Description

BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). BioMarin has a hemophilia A gene therapy and a treatment for achondroplasia in late-stage clinical trials.


Visit Website

BMRN Earnings

EPS -0.32 P/E Ratio 0.00
Previous Earnings Thu, Feb 21, 2019
Latest Earnings Thu, Apr 25, 2019 (81 days ago) -1.75%

BMRN Dividend

Yield --
Ex-Date --
Pay Date --
History --

BMRN Charts

$80.06
52 Week Range
$106.74
Dec 24, 2018
Oct 17, 2018



Symbol Price Day % YTD %
BMRN $83.99 1.25% -1.14%

Symbol Surfing

How can we make Symbol Surfing better?

info@symbolsurfing.com

Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.



©2019 Symbol Surfing All Rights Reserved.

Cookies Policy | Terms Of Service | Privacy Policy